NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population

Several scores based on easily measurable biochemical and clinical parameters, including the fatty liver index (FLI), hepatic steatosis index (HSI), lipid accumulation product (LAP), and NAFLD liver fat score (LFS), have been developed for the detection of NAFLD. However, comparative information regarding the efficacy of these scores for predicting NAFLD...
Read MoreComparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

The exclusion of other chronic liver diseases including “excess” alcohol intake are usually necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, “positive criteria” to diagnose the disease are required. A panel of international experts from 22 countries...
Read MoreMAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease

From NAFLD to MAFLD: when pathophysiology succeeds

Two new position papers convincingly propose that non-alcoholic fatty liver disease needs a new name — metabolic associated fatty liver disease (MAFLD). A new name for this disease affecting nearly one billion people globally is overdue, as knowledge gained from the past decades has definitely demonstrated that MAFLD is a purely metabolic disorder...
Read MoreFrom NAFLD to MAFLD: when pathophysiology succeeds

Non-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.

Several studies have investigated the association between serum uric acid and metabolic syndrome / NAFLD. Four meta-analysis on retrospective and prospective studies confirmed this association, especially in women. However, most of the studies included in the analysis were performed on Asian populations. Despite high quality and large population...
Read MoreNon-alcoholic fatty liver disease: correlation with hyperuricemia in a European Mediterranean population.

Experimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.

In a CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis, S. Lefere et al. studied the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. To examine the pathophysiological sequence of steatohepatitis...
Read MoreExperimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.

Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.

A. de Gottardi et al. (Gastroenterology and Hepatology, Ente Ospedaliero Cantonale, Lugano, Switzerland) present a case of SARS-CoV-2 infection reported in the literature in a liver transplanted patient. In this immunosuppressed patient, the evolution of the infection was characterized by a moderate to severe interstitial pneumonia...
Read MoreClinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

In an experimental study, S. Lefere et al. investigated the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. The authors employed the CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis...
Read MoreDifferential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.